Prior to receiving FDA approval, new treatments typically go through 3 phases of clinical [human] trials. The problem is that thousands of currently registered clinical trials never get off the ground due to a lack of participants. Though a centralized database of registered clinical trials exists on www.ClinicalTrials.gov, the lack of common language and eligibility matrix has resulted in a frustrating bottleneck between supply [patients] and demand [open clinical trials]. Patients suffering from afflictions that currently have treatments in clinical trial stages often have to go through an arduous search that may not always yield relevant trials or the contact information required to apply.
Enter the Antidote database. Antidote asks a series of targeted questions and creates a smart search that specifically narrows down relevant trials where a patient fits the eligibility criteria. Unlike the database on ClinicalTrials.gov, Antidote utilizes sophisticated algorithms and AI and can also search for synonyms of different conditions that may not otherwise show up in a search.
The new database platform is finding a ready audience amongst researchers, disease entity groups, medicinal entities and patients, and it will have far-reaching implications for the application and possible success of current clinical trials. Amazingly, by simply expanding the pool of patients and facilitating participation in clinical trials, Antidote will broaden the scope of clinical trials and help stagnating trials achieve results, thereby expanding the number of active clinical trials and accelerating potential treatment options for a wide range of disease, trauma and injury.